Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial
European Journal of Cancer2013Vol. 49(17), pp. 3609–3615
Citations Over TimeTop 10% of 2013 papers
Michele Reni, Stefano Cereda, Michèle Milella, Anna Novarino, Alessandro Passardi, Andrea Mambrini, Giuseppe Di Lucca, Giuseppe Aprile, Carmen Belli, Marco Danova, Francesca Bergamo, Enrico Franceschi, Clara Fugazza, Domenica Ceraulo, Eugenio Villa
Related Papers
- → Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors(2013)83 cited
- → Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?(2019)28 cited
- → Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials(2015)22 cited
- → Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint(2011)19 cited
- Progression-free survival rate as primary endpoint for phase-II cancer clinical trialsapplication to mesothelioma(2010)